| 利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展 |
| |
| 引用本文： | 谢海平,林帆,陈彦,郑铭. 利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2020, 36(9): 2111-2114 |
| |
| 作者姓名： | 谢海平 林帆 陈彦 郑铭 |
| |
| 作者单位： | 福建医科大学省立临床医学院,福州350000;福建省立医院 老年科,福州350000;福建省立金山医院(福建省立医院南院)内科,福州350001;福建省立医院 干部特诊科,福州350000 |
| |
| 摘 要： | 非酒精性脂肪性肝病(NAFLD)是常见的慢性肝脏疾病,患病率逐年上升,胰岛素抵抗及氧化应激是主要发病机制,目前仍缺乏有效的治疗药物。胰岛素抵抗也是引起2型糖尿病的主要发病机制,糖尿病患者NAFLD患病率较非糖尿病患者高。利拉鲁肽是人胰高血糖素样肽1受体激动剂,可改善胰岛素抵抗,越来越多研究发现利拉鲁肽对2型糖尿病合并NAFLD有一定疗效,相关机制仍未完全明确。就利拉鲁肽治疗2型糖尿病合并NAFLD的疗效及相关机制的研究进展进行综述。
|
| 关 键 词： | 非酒精性脂肪性肝病 糖尿病,2型 利拉鲁肽 |
Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease |
| |
| XIE Haiping,LIN Fan,CHEN Yan,ZHENG Ming. Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J]. Chinese Journal of Clinical Hepatology, 2020, 36(9): 2111-2114 |
| |
| Authors: | XIE Haiping LIN Fan CHEN Yan ZHENG Ming |
| |
| Affiliation: | (Provincial Clinical Medical College,Fujian Medical University,Fuzhou 350000,China;Department of Geriatrics,Fujian Provincial Hospital,Fuzhou 350000,China;Department of Cadre Special Diagnosis,Fujian Provincial Hospital,Fuzhou 350000,China;Department of Internal Medicine,Fujian Provincial Jinshan Hospital(South Branch of Fujian Provincial Hospital),Fuzhou 350001,China) |
| |
| Abstract: | Nonalcoholic fatty liver disease(NAFLD)is a common chronic liver disease,and its prevalence rate is increasing year by year.Insulin resistance and oxidative stress are the main pathogeneses of NAFLD,and there are still no effective drugs for the treatment of this disease.Insulin resistance is also a main pathogenesis of type 2 diabetes,and people with type 2 diabetes have a higher prevalence rate of NAFLD than those without diabetes.Liraglutide is a human glucagon-like peptide-1 analogue and can improve insulin resistance,and more and more studies have found that liraglutide has a certain therapeutic effect in patients with type 2 diabetes and NAFLD,while related mechanisms have not been fully clarified.This article reviews the therapeutic effect and related mechanisms of liraglutide in the treatment of type 2 diabetes and NAFLD. |
| |
| Keywords: | non-alcoholic fatty liver disease diabetes mellitus,type 2 liraglutide |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
